IN8bio Inc (INAB) News

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

IN8bio Announces Clinical Pipeline Prioritization to Focus on INB-100 for Acute Myeloid Leukemia

Top Priority Clinical Program: Working to drive significant value creation with INB-100 for AML; ongoing trial...

IN8bio to Present at the H.C. Wainwright 26th Annual Global Investment Conference

NEW YORK, Aug. 29, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage...

Form 424B5 - Prospectus [Rule 424(b)(5)]

Form 8-K - Current report

IN8bio Solidifies Position as a Clinical Leader of Gamma-Delta T Cell Therapy in Oncology with 100% of Treated AML Patients in Complete Remission and Receives FDA Guidance for Registrational Trial of INB-100

Received FDA guidance on the registrational path for INB-100 in acute myeloid leukemia (AML), an...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

IN8bio Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights

- Presented positive Phase 1 data showing 100% 1-year complete remission (CR) in evaluable patients with...